AlzeCure Pharma AB (FRA:AC6) ROCE % : -79.32% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is AlzeCure Pharma AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AlzeCure Pharma AB's annualized ROCE % for the quarter that ended in Sep. 2024 was -79.32%.

AlzeCure Pharma AB ROCE % Historical Data

The historical data trend for AlzeCure Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB ROCE % Chart

AlzeCure Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-24.15

-49.65

-107.45

-117.44

-87.11

AlzeCure Pharma AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-81.32	-140.62	-206.13	-129.58	-79.32

AlzeCure Pharma AB ROCE % Calculation

AlzeCure Pharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.322	/	( ( (6.443 - 0.942)	+	(2.861 - 0.735) )	/ 2 )
	=	-3.322	/	( (5.501	+	2.126)	/ 2 )
	=	-3.322	/	3.8135
	=	-87.11 %

AlzeCure Pharma AB's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-2.624	/	( ( (4.186 - 0.698)	+	(3.748 - 0.62) )	/ 2 )
	=	-2.624	/	( ( 3.488	+	3.128 )	/ 2 )
	=	-2.624	/	3.308
	=	-79.32 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

AlzeCure Pharma AB (FRA:AC6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AlzeCure Pharma AB ROCE % Related Terms

Thank you for viewing the detailed overview of AlzeCure Pharma AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AlzeCure Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (FRA:AC6) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ALZCUR:Sweden

Address

Halsovagen 7, Huddinge, SWE, SE 141 57

Website

https://www.alzecurepharma.se

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.

AlzeCure Pharma AB Headlines

No Headlines